Advanced Instruments launches three new levels of Osmometer Standard Solutions

NewsGuard 100/100 Score

Advanced Instruments is pleased to introduce three new levels of Osmometer Standard Solutions to its product offering. The 200, 400 and 1000 mOsm/kg H20 level standards are NIST- traceable salt solutions that are packaged in 2mL ampules, 10 ampules per box. The kits are available for immediate release.

“The tighter new USP requirement created the need for a broader offering of osmolality standard solutions, particularly in the 200 to 1000 mOsm/kg range where many of the pharmaceutical, parenteral and IV drug products are formulated”

The new levels were created in response to recent changes in the USP Chapter <785> Osmolality and Osmolarity. The new requirement specifies that instrument calibration must be confirmed with at least one solution that lies within 50 mOsm/kg H20 of the value of the test solution or the center of the expected range of osmolality of the test solution.

In the past, researchers were required to verify calibration with 2 solutions which spanned the expected range of the test solution, and there was no requirement for how close these levels needed to be to the test solution.

"The tighter new USP requirement created the need for a broader offering of osmolality standard solutions, particularly in the 200 to 1000 mOsm/kg range where many of the pharmaceutical, parenteral and IV drug products are formulated," says Kelly Peterson, Product Manager.

"Pharmaceutical customers were coming to us and asking if we could provide these solutions. With our position as the industry leader in osmometry, we felt an obligation to deliver these products to our customers," Peterson said. "These new levels complement the current AI offering of osmolality standards. Customers now have standard solutions that are commercially available in order to be fully compliant with USP General Chapter <785>."


Source:

Advanced Instruments, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status